← All trials
NCT06612255
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2024
- Primary completion
- Sep 11, 2024
- Completion date
- Sep 11, 2024
- First posted
- Sep 25, 2024
- Last posted
- Nov 25, 2024
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Melinta TherapeuticsLead sponsor
- Department of Health and Human ServicesCollaborator
- Melinta TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.